Comparative cardiovascular effects of thiazolidinediones

Clinical Governance: An International Journal

ISSN: 1477-7274

Article publication date: 9 August 2011

Citation

(2011), "Comparative cardiovascular effects of thiazolidinediones", Clinical Governance: An International Journal, Vol. 16 No. 3. https://doi.org/10.1108/cgij.2011.24816caa.011

Publisher

:

Emerald Group Publishing Limited

Copyright © 2011, Emerald Group Publishing Limited


Comparative cardiovascular effects of thiazolidinediones

Comparative cardiovascular effects of thiazolidinediones

Article Type: Reviews of effectiveness From: Clinical Governance: An International Journal, Volume 16, Issue 3

Loke, Y.K., Kwok, C.S., Singh, S.Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studiesBMJ2011Vol. 342d1309

This review concluded that in patients with type 2 diabetes, rosiglitazone was associated with significantly higher odds of congestive heart failure, myocardial infarction, and death, than pioglitazone, in real-world settings. This was a generally well-conducted review. The authors acknowledged the methodological limitations of the evidence available and the conclusions are likely to be reliable.